This story has been updated to include comments from a conference call with investors.
NEW YORK – Meridian Bioscience reported on Friday that its fiscal fourth quarter revenues increased 26 percent year over year, with reagent sales more than offsetting a dip in diagnostics revenues.
For the three months ended Sept. 30, the firm reported revenues of $64.2 million up from $50.8 million a year ago and beating the average consensus Wall Street estimate of $59.6 million.